Taken together, these data demonstrated that GIT1 is expressed at lower protein levels in ER(−) breast tumours than ER(+) tumours and that ER(−) breast cancer patients with high levels of GIT1 have a better prognosis than those with low levels. This evidence concerns the gene GIT1 and breast carcinoma.